Global Newsroom

KING OF PRUSSIA, PA

• Etranacogene dezaparvovec (AMT-061) is an investigational gene therapy that may potentially provide people with hemophilia B with years of functional levels of Factor IX, a blood-clotting protein that prevents excessive bleeding.

• uniQure will complete the Phase 3 HOPE-B trial and scale up manufacture for initial commercial supply under an agreed plan with CSL Behring.

King of Prussia, Pa

The label update is based on open label extension data from the landmark PATH (Polyneuropathy And Treatment with Hizentra) study

Osaka, JAPAN and King of Prussia, Pa., USA

Phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) clinical trial sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), did not meet its endpoints to show efficacy in adults hospitalized with COVID-19

CSL continues to provide medicines to patients around the world.

Here's how CSL is working around the world with academia, industry and governments to combat COVID-19

NEW YORK

• TransplantLyfe is an online community for those living with an organ transplant, their support partners and donors to share experiences, find one-on-one mentorships and help individuals feel safe as they embrace struggles unique to transplantation, regardless of their physical location.

• TransplantLyfe addresses a major unmet need for those living with organ transplantation: most notably, the support and communication gap between individuals with similar experiences in the transplant journey.

KING OF PRUSSIA, Pa.

- Reduction in number of attacks is leading factor when evaluating prophylactic therapy

KING OF PRUSSIA, Pa. and PHILADELPHIA, Pa.

- 6 Urban League Affiliates across U.S. to participate -- starting with Philadelphia

KING OF PRUSSIA, Pa.

Global biotherapeutics leader reinforces commitment to cardiovascular research: Hosts Learning Studio with prominent cardiovascular thought leaders to discuss emerging treatment targets

KING OF PRUSSIA, Pa.

The AEGIS-II trial is evaluating the efficacy and safety of CSL112 (apolipoprotein A-1 [human]) during the high-risk 90-day period following a heart attack

KING OF PRUSSIA, Pa.

• Both US and European regulators grant special designation
• Phase 1 clinical development underway for CSL889

KING OF PRUSSIA, Pa.

- Forbes Recognizes Global Biotechnology Leader for Fourth Straight Year

MELBOURNE, AU and KING OF PRUSSIA, PA

• Vaccine, hyperimmune and monoclonal antibodies all in clinical stages as potential preventative or treatment options in the fight against COVID-19

• Advancements across Cell and Gene Therapy, Recombinant Technology, Plasma Fractionation and Cell and Egg-Based Vaccines scientific platforms all spotlighted including internal progression, acquisitions and alliances

Osaka, JAPAN and King of Prussia, Pa., USA

• The Alliance’s anti-COVID-19 Hyperimmune Globulin (CoVIg-19) medicine is under evaluation as part of the trial and may become one of the earliest treatments for hospitalized individuals at risk for serious complications of COVID-19
• The CoVIg-19 Plasma Alliance urges anyone who has recovered from COVID-19 to consider donating plasma. To learn more, please visit TheFightIsInUs.org

KING OF PRUSSIA, PA
HAEGARDA is the first and only subcutaneous prophylactic HAE treatment approved for children 6 years of age and older

MARBURG, Germany

- Bronze sponsor CSL Behring also establishes programme for attendees to support Alpha 1 disease awareness

• On behalf of the CoVIg-19 Plasma Alliance and other plasma companies, Perreault urges people who have recovered from COVID-19 to consider donating plasma. To learn how and where to donate plasma, please visit TheFightIsInUs.org.

• The more convalescent plasma the industry collects – and the more quickly it does so – directly influences the timeline to deliver a potential hyperimmune globulin for COVID-19.

• The clinical trial, sponsored by The National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH), in which the CoVIg-19 Plasma Alliance will participate is expected to begin soon.

KING OF PRUSSIA, Pa.

• Five coagulation researchers named this year’s recipients
• Professor Heimburger Awards and ISTH Virtual Congress sponsorship showcase CSL Behring’s commitment to hematology research

KING OF PRUSSIA, Pa.

- Phase II placebo-controlled study will assess the safety and efficacy of CSL312 for the treatment of patients with severe respiratory distress due to COVID-19 related pneumonia
- CSL Behring now evaluating 5 approaches to preventing and treating COVID-19

KING of PRUSSIA, Pa.

• Unique gene therapy has the potential to be one of the first to market treatments to provide potentially long-term benefits with only one dose
• CSL Behring builds on legacy of delivering innovative treatment options for people with Hemophilia B